Trump secures agreements with major drugmakers to lower Medicaid prescription costs for Americans

The administration announced that nine additional major drugmakers — Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi — have agreed to the White House’s most-favored-nation pricing framework for Medicaid, bringing the total to 14 of the 17 largest global firms; the signatories also committed $150 billion in new domestic manufacturing and R&D investment and some agreed to donate active pharmaceutical ingredients to a Strategic API Reserve. The deals are being presented as a policy win with potential price pressure on U.S. drug reimbursements and a political lever (including threats of tariffs), while the administration plans a consumer-facing site (TrumpRX.gov) slated for January 2026. Markets should watch policy implementation details and potential margin implications for pharma earnings versus the offsetting $150 billion investment commitments and supply-chain resilience measures.

Analysis

Market structure: The immediate winners are large, diversified pharma that signed deals (PFE, AZN, NVS, SNY, GSK) because they avoided tariffs and secured $150bn of domestic capex commitments; losers are high-US-price, specialty-biologic franchises (certain AMGN, NVO exposures) facing anchored Medicaid pricing and potential global price convergence. Pricing power will shift toward governments as US Medicaid anchors to other countries, implying commercial price erosion for top-selling branded drugs of ~5–20% over 1–3 years depending on product mix and rebate passthrough. Domestic API/CMO investment and SAPIR donations signal increased upstream supply resilience over 2–5 years, easing commodity/API shortages but raising short-term capex-driven costs.

Risk assessment: Tail risks include large litigation/antitrust suits by manufacturers, countries retaliating on trade (tariff spillovers), or companies walking back investment commitments; any of these could move equities ±15–30% in idiosyncratic names. Near-term (days–weeks) risk is headline-driven volatility around TrumpRX.gov and CMS rule language; medium-term (quarters) risk is margin guidance reset at earnings; long-term (1–3 years) risk is structural margin compression offset by capex efficiency gains. Hidden dependencies: Medicaid already gets deep rebates—net U.S. impact depends on rebate pass-through mechanics, exchange-rate effects, and how companies reprice internationally.

Trade implications: Tactical long on diversified non-U.S.-centric pharma (GSK, NVS) and selective shorts or long-dated put spreads on US-price-sensitive innovators (AMGN, NVO). Use 3–12 month option structures to express views: buy 6–9 month put spreads on AMGN/NVO (caps losses) and buy 9–12 month call spreads on PFE/ BMY to play manufacturing/R&D upside from $150bn commitments. Rotate out of small-cap biotech and into large-cap pharm and industrial suppliers; expect rebalancing flows into bonds (credit widening for pharma) and modest USD strength if tariffs/rescue packages re-emerge.

Contrarian angles: Consensus assumes straight-through 20% price cuts; that underestimates companies’ ability to offset via list price increases elsewhere, contracting tactics, and accelerated biosimilar deals—net earnings risk may be overstated for diversified players. Historical parallels (previous US price-threat episodes 2012–2020) show headline-driven 10–20% selloffs that retraced once implementation details were delayed or softened; therefore, deep equity dips in large-cap pharm could be buying opportunities with 12–24 month horizons. Unintended consequence: accelerated domestic consolidation and reduced innovation in marginal therapy areas, which favors big-cap R&D-focused names for takeover targets.

Key Decisions for Investors

• Establish a 2–3% long position split between NVS and GSK (1–1.5% each) over 6–12 months to capture resilience from non-US revenue mix and potential upside from domestic manufacturing investments; place stop-loss at -8% and reassess after next two earnings releases.
• Initiate a 1–2% short-equivalent position in AMGN and NVO (total 2–4%) via 6–9 month put spreads (e.g., buy 5–10% OTM puts and sell deeper OTM puts to cap premium) to capture 15–30% downside if Medicaid pricing anchors lead to >5–10% net price erosion in core franchises.
• Buy a 1–2% position in BMY or a 9–12 month call spread on PFE (moderately OTM, capped cost) to play upside from $150bn domestic capex and contract wins; target 12–18% upside and take profits on any >15% move.
• Allocate a 0.5–1% event-driven tranche to trade volatility around regulatory catalysts: increase short exposure if CMS final rule reduces net prices >10% for top 50 drugs or cut shorts and add longs if implementation timelines slip beyond 12 months—monitor HHS rule releases and company guidance within the next 30–60 days.